News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
News App to support people with depression launches in GB A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.
News Guidance creates access gap in UK for GPP drug Spevigo People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.
News Streeting pledges clinical trial signups in the NHS App Millions of people in the UK will be given the opportunity to take part in clinical trials via the NHS App.
News NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.
Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face